Roche ended two Huntington’s disease antisense programs with Ionis Pharmaceuticals after disappointing clinical outcomes, adding to a run of recent setbacks for neurodegeneration assets. In a letter to the Huntington’s community, Roche said it discontinued the Phase 2 GENERATION HD2 study of tominersen after the program failed to meet a key efficacy objective, and stopped a separate investigational antisense therapy (RG6496) following new safety-relevant animal data. Roche characterized both decisions as data-driven and noted the trials coincided “by chance,” while stating it will continue collaborating on other programs with Ionis. For tominersen, Roche previously paused or terminated other studies before, making GENERATION HD2 the latest clinical disappointment in the molecule’s long development history. The moves arrive amid broader antisense and RNA-therapy pressure in cardiometabolic and neurodegenerative indications. Earlier, Ionis and AstraZeneca also disclosed a Phase 3 failure in transthyretin amyloidosis cardiomyopathy tied to eplontersen (Wainua), underscoring how the modality is facing heightened scrutiny on efficacy durability. For Ionis, the latest Huntington’s cancellations follow a period of stock volatility and program restarts, leaving the company to focus resources on remaining partnered and internal platforms as well as other application areas for its antisense and related modalities.